SMART designs in cancer research: Past, present, and future

Clinical Trials

Volumn 11, Issue 4, 2014, Pages 445-456

  Kidwell, Kelley M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN;

BONE TRANSPLANTATION; CANCER RESEARCH; CANCER SURVIVAL; CANCER THERAPY; CONFERENCE PAPER; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; LUNG SMALL CELL CANCER; LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; NEUROBLASTOMA; OVERALL SURVIVAL; PHYSICIAN; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEQUENTIAL MULTIPLE ASSIGNMENT RANDOMIZED TRIAL DESIGN;

EID: 84906094418     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774514525691     Document Type: Conference Paper

References (65)

1. GLOBOCAN. GLOBOCAN 2008 section of cancer information. Available at: http://www.who.int/mediacentre/factsheets/fs297/en/index.html (2013).
2. SiegelRDeSantisCVirgoK. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin2012; 62(4): 220-41. Available at: http://dx.doi.org/10. 3322/caac.21149
3. Chakraborty B. Dynamic treatment regimes for managing chronic health conditions: A statistical perspective. Am J Public Health. 2011 ; 101: 40-45
4. Murphy SA. An experimental design for the development of adaptive treatment strategies. Stat Med. 2005 ; 24: 1455-81
5. Lavori PW, Dawson R, Rush AJ. Flexible treatment strategies in chronic disease: Clinical research implications. Biol Psychol. 2000 ; 48: 605-14
6. Lavori PW, Dawson R. Dynamic treatment regimes: Practical design considerations. Clin Trials. 2004 ; 1: 9-20
7. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med. 1995 ; 332: 1671-77
8. Lavori PW, Dawson R. Adaptive treatment strategies in chronic disease. Annu Rev Med. 2008 ; 59: 443-53
9. Murphy SA, Oslin D, Rush SJ, Zhu J. Methodological challenges in constructing effective treatment sequences for chronic psychiatric disorders. Neuropsychopharmacology. 2007 ; 32: 257-62
10. Lei H, Nahum-Shani I, Lynch K, Oslin D, Murphy SA. A 'SMART' design for building individualized treatment sequences. Annu Rev Clin Psychol. 2012 ; 8: 21-48
11. Oetting AI, Levy JA, Weiss RD, Murphy SA Causality and Psychopathology: Finding the Determinants of Disorders and Their Cures. Shrout P Keyes K Ornstein K, ed. Arlington, VA: American Psychiatric Publishing, Inc ; 2011: 179-205.
12. Nahum-Shani I, Qian M, Almirall D, et al. Experimental design and primary data analysis methods for comparing adaptive interventions. Psychol Methods. 2012 ; 17: 457-77
13. Rosner F. The ethics of randomized clinical trials. Am J Med. 1987 ; 82: 283-90
14. Ko JH, Wahed AS. Up-front versus sequential randomizations for inference on adaptive treatment strategies. Stat Med. 2012 ; 31: 812-30
15. Robins JM. A new approach to causal inference in mortality studies with sustained exposure periods - Application to control of the healthy worker survivor effect. Math Model. 1986 ; 7: 1393-512
16. Rubin DB. Estimating causal effects of treatments in randomized and non-randomized studies. J Educ Psychol. 1974 ; 66: 688-701
17. RobinsJ. Causal inference from complex longitudinal data. In BerkaneM (ed.). Latent Variable Modeling and Applications to Causality (Volume 120 of Lecture Notes in Statistics). Springer, New York, 1997, pp. 69-117. Available at: http://dx.doi.org/10.1007/978-1-4612-1842-5-4
18. Lunceford JK, Davidian M, Tsiatis AA. Estimation of survival distributions of treatment policies in two-stage randomization designs in clinical trials. Biometrics. 2002 ; 58: 48-57
19. Bembom O, van der Laan MJ. Analyzing sequentially randomized trials based on causal effect models for realistic individualized treatment rules. Stat Med. 2008 ; 27: 3689-716
20. Chakraborty B, Murphy SA. Dynamic treatment regimes. Ann Rev Stat Appl. 2014 ; 1: 1.1-18
21. Huang X, Cormier JN, Pisters PWT. Estimation of the causal effects on survival of two-stage nonrandomized treatment sequences for recurrent diseases. Biometrics. 2006 ; 62: 901-09
22. HernnMALanoyECostagliolaDRobinsJM. Comparison of dynamic treatment regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol2006; 98(3): 237-42. Available at: http://dx.doi.org/10.1111/j.1742-7843.2006.pto-329. x
23. Li Z, Valenstein M, Pfeiffer P, Ganoczy D. A global logrank test for adaptive treatment strategies based on observational studies. Stat Med. 2013 ; 55: 760-71
24. Joss RA, Alberto P, Bleher EA, et al. Combined-modality treatment of small-cell lung cancer: Randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest. Ann Oncol. 1994 ; 5: 921-28
25. Tummarello D, Mari D, Graziano F, et al. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses. Cancer. 1997 ; 80: 2222-29
26. Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: A randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 2001 ; 98: 548-53
27. Thomas X, Raffoux E, Botton Sd, et al. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: A trial by the Acute Leukemia French Association (ALFA) Group. Leukemia. 2007 ; 21: 453-61
28. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999 ; 341: 1165-73
29. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children's oncology group study. J Clin Oncol. 2009 ; 27: 1007-13
30. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP verses CHOP alone or with maintenance Rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006 ; 24: 3121-27
31. Van Oers MHJ, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood. 2006 ; 108: 3295-301
32. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006 ; 108: 4003-08
33. Thall PF, Millikan RE, Sung HG. Evaluating multiple treatment courses in clinical trials. Stat Med. 2000 ; 30: 1011-128
34. Mateos MV, Orio A, Martínez-López J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial. Lancet Oncol. 2010 ; 11: 934-41
35. Auyeung SF, Long Q, Royster EB, et al. Sequential multiple-assignment randomized trial design of neurobehavioral treatment for patients with metastatic malignant melanoma undergoing high-dose interferon-alpha therapy. Clin Trials. 2009 ; 6: 480-90
36. Thall PF, Wooten LH, Logothetis CJ, Millikan RE, Tannir NM. Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med. 2007 ; 26: 4687-702
37. Wahed AS, Tsiatis AA. Optimal estimator for the survival distribution and related quantities for treatment policies in two-stage randomization designs in clinical trials. Biometrics. 2004 ; 60: 124-33
38. Guo X, Tsiatis AA. A weighted risk set estimator for survival distributions in two-stage randomization designs with censored survival data. Int J Biostat. 2005 ; 1: 1-15
39. Wahed AS, Tsiatis AA. Semiparametric efficient estimation of survival distributions in two-stage randomisation designs in clinical trials with censored data. Biometrika. 2006 ; 93: 163-77
40. Lokhnygina Y, Helterbrand JD. Cox regression methods for two-stage randomization designs. Biometrics. 2007 ; 63: 422-28
41. Feng W, Wahed AS. Supremum weighted log-rank test and sample size for comparing two-stage adaptive treatment strategies. Biometrika. 2008 ; 95: 695-707
42. Tang X, Wahed AS. Comparison of treatment regimes with adjustment for auxiliary variables. J Appl Stat. 2011 ; 38: 2925-38
43. Wang L, Rotnitzky A, Lin X, Millikan RE, Thall PF. Evaluation of viable dynamic treatment regimes in a sequentially randomized trial of advanced prostate cancer. J Am Stat Assoc. 2012 ; 107: 493-508
44. Wahed AS, Thall PF. Evaluating joint effects of induction-salvage treatment regimes on overall survival in acute leukaemia. J R Stat Soc Ser C Appl Stat. 2013 ; 62: 67-83
45. Zhao Y, Zeng D, Socinski MA, Kosorok MR. Reinforcement learning strategies for clinical trials in nonsmall cell lung cancer. Biometrics. 2011 ; 67: 1422-33
46. Goldberg Y, Kosorok MR. Q-learning with censored data. Ann Stat. 2012 ; 40: 529-60
47. Kidwell KM, Wahed AS. Weighted log-rank statistic to compare shared-path adaptive treatment strategies. Biostatistics. 2013 ; 14 (2). 299-312
48. Miyahara S, Wahed AS. Weighted Kaplan-Meier estimators for two-stage treatment regimes. Stat Med. 2010 ; 29: 2581-91
49. Thall PF, Logothetis C, Pagliaro LC, et al. Adaptive therapy for androgen-independent prostate cancer: A randomized selection trial of four regimens. J Natl Cancer Inst. 2007 ; 99 (21). 1613-22
50. Bembom O, van der Laan MJ. Statistical methods for analyzing sequentially randomized trials. J Natl Cancer Inst. 2007 ; 99: 1577-82
51. Thall PF. A review of phase 2-3 clinical trial designs. Lifetime Data Analysis. 2008 ; 14: 37-53
52. Wolbers M, Helterbrand JD. Two-stage randomization designs in drug development. Stat Med. 2008 ; 27: 4161-74
53. Buyze J, Rompaye BV, Goetghebeur E. Designing a sequentially randomized study with adherence enhancing interventions for diabetes patients. Stat Med. 2010 ; 29: 1114-26
54. Buyze J, Goetghebeur E. Evaluating dynamic treatment strategies: Does it have to be more costly?. Pharm Stat. 2012 ; 12: 35-42
55. Feng W, Wahed AS. Sample size for two-stage studies with maintenance therapy. Stat Med. 2009 ; 28: 2028-41
56. Li Z, Murphy SA. Sample size formulae for two-stage random trials with survival outcomes. Biometrika. 2011 ; 98: 503-18
57. Orellana L, Rotnitzky A, Robins JM. Dynamic regime marginal structural mean models for estimation of optimal dynamic treatment regimes, part I: Main content. Int J Biostat. 2010 ; 6 :
58. Dawson R, Lavori PW. Placebo-free designs for evaluating new mental health treatments: The use of adaptive treatment strategies. Stat Med. 2004 ; 23: 3249-62
59. Dawson R, Lavori PW. Sample size calculations for evaluating treatment policies in multi-stage designs. Clin Trials. 2010 ; 7: 643-52
60. Zhao Y, Zeng D, Rush AJ, Kosorok MR. Estimating individualized treatment rules using outcome weighted learning. J Am Stat Assoc. 2012 ; 107: 1106-18
61. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design. Control Clin Trials. 2004 ; 25: 119-42
62. Schneider LS, Tariot PN, Lyketsos CG, et al. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry. 2001 ; 9: 346-60
63. Murphy SA, Lynch KG, McKary JR, Oslin D, Tenhave T. Developing adaptive treatment strategies in substance abuse research. Drug Alcohol Depend. 2007 ; 88: S24-30
64. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: The what, why and how. BMC Med Res Methodol. 2010 ; 10: 1
65. Almirall D, Compton SN, Gunlicks-Stoessel M, Duan N, Murphy SA. Designing a pilot sequential multiple assignment randomized trial for developing an adaptive treatment strategy. Stat Med. 2012 ; 31: 1887-902